WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H571444
CAS#: 79-93-6
Description: Phenaglycodol is a tranquilizing agent previously used to treat a variety of nervous conditions and tensions including anxiety and depression. It has also been effective as an anticonvulsive agent against seizures.
Hodoodo Cat#: H571444
Name: Phenaglycodol
CAS#: 79-93-6
Chemical Formula: C11H15ClO2
Exact Mass: 214.08
Molecular Weight: 214.689
Elemental Analysis: C, 61.54; H, 7.04; Cl, 16.51; O, 14.90
Synonym: Phenaglycodol; Acalmid; Atadiol; Felixin; Puasital; Sedapsin; Sinforil; NSC 169451; NSC-169451; NSC169451
IUPAC/Chemical Name: 2,3-Butanediol, 2-(4-chlorophenyl)-3-methyl- (9CI)
InChi Key: HTYIXCKSEQQCJO-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H15ClO2/c1-10(2,13)11(3,14)8-4-6-9(12)7-5-8/h4-7,13-14H,1-3H3
SMILES Code: CC(O)(C1=CC=C(Cl)C=C1)C(O)(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 214.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Dolfini E, Reschiotto C, Testa R. Toxicological and pharmacokinetic studies on phenaglycodol in rats. GLC assay for its determination in plasma. Farmaco Prat. 1980 Nov;35(11):564-70. PubMed PMID: 7461103.
2: Rickels K, Csanalosi I, Gratch M, Gingrich RL Jr, Kelly EA, Mirman MJ. Phenaglycodol in anxiety: a controlled study. Curr Ther Res Clin Exp. 1975 Jan;17(1):23-31. PubMed PMID: 806427.
3: CHIN L, SWINYARD EA. Pentylenetetrazol seizure threshold in meprobamate- and phenaglycodol-treated mice. J Am Pharm Assoc Am Pharm Assoc. 1959 Jan;48(1):6-8. PubMed PMID: 13610718.
4: BACHMAN H, FREUND J. Use of phenaglycodol for alleviation of nervous tension in patients with tuberculosis. Am Pract Dig Treat. 1958 Mar;9(3):397-400. PubMed PMID: 13509014.
5: Brauzer B, Goldstein BJ. Placebo-controlled evaluation of phenaglycodol in anxious, depressed outpatients. J Clin Pharmacol New Drugs. 1972 Jul;12(7):280-5. PubMed PMID: 4557536.
6: BISIANI M, FRESIA P, GENOVESE E. [Studies on a new tranquilizing agent, 2-para-chlorophenyl-3-methyl-2,3-butandiol (phenaglycodol)]. Boll Soc Ital Biol Sper. 1957 Jun;33(6):932-6. Italian. PubMed PMID: 13499748.
7: GRUBER CM Jr, MOSIER JM. Anticonvulsant activity: phenobarbital-methamphetamine-phenaglycodol. Antibiotic Med Clin Ther (New York). 1958 Apr;5(4):235-41. PubMed PMID: 13521762.
8: CARTER CH. Phenaglycodol, an anticonvulsant effective in grand mal and petit mal seizures. Antibiotic Med Clin Ther (New York). 1958 Nov;5(11):675-8. PubMed PMID: 13595623.
9: ZUKIN P, ARNOLD DG, KESSLER CR. Comparative effects of phenaglycodol and meprobamate on anxiety reactions. J Nerv Ment Dis. 1959 Aug;129:193-5. PubMed PMID: 13847900.
10: DENYSE DL. Clinical observations with phenaglycodol in hypertension with anxiety states. R I Med J. 1957 Sep;40(9):514-5 passim. PubMed PMID: 13477861.
11: KATO R. Modifications of the toxicity of strychnine and octomethylpyrophosphoramide (OMPA) induced by pretreatment with phenaglycodol and thiopental. Arzneimittelforschung. 1961 Aug;11:797-8. PubMed PMID: 14454292.
12: SETTEL E. Phenaglycodol for geriatric agitation. Geriatrics. 1957 Oct;12(10):607-11. PubMed PMID: 13474279.
13: SETTEL E. An analysis of the analgesic effect of dextropro-poxyphene hydrochloride, phenaglycodol, and aspirin combination (darvo-tran). Antibiotic Med Clin Ther (New York). 1959 Sep;6:512-7. PubMed PMID: 14445201.
14: IMBERCIADORI E. [Early results of the use of 2-p-chlorophenyl-3-methyl-2,3-butanediol (phenaglycodol) in neuropsychiatric therapy]. Minerva Med. 1960 Mar 3;51:757-60. Italian. PubMed PMID: 13852743.
15: FRIEND DG. Current concepts in the therapy. Tranquilizers. III. Meprobamate, phenaglycodol and chlordiazepoxide. N Engl J Med. 1961 Apr 27;264:870-3. PubMed PMID: 13702063.
16: QUADRIO A. [Various experimental notes on the effect of phenaglycodol on several mental functions]. Clin Ter. 1959 Jun;16(6):583-9. Italian. PubMed PMID: 13671735.
17: CERRI O. [Determination of phenaglycodol]. Boll Chim Farm. 1958 May;97(5):261-2. Italian. PubMed PMID: 13560622.
18: CIMA L, FASSINA G. [Identification and urinary elimination of phenaglycodol]. Farmaco Prat. 1959 Jul;14:416-23. Italian. PubMed PMID: 13849393.
19: KUGELMASS IN. Phenaglycodol therapy in cerebral palsy. Ann N Y Acad Sci. 1958 Oct 15;72(8):271-92. PubMed PMID: 13583888.
20: GRUBER CM Jr, MOSIER JM. Phenaglycodol: a new antiepileptic agent. Proc Soc Exp Biol Med. 1957 Feb;94(2):384-5. PubMed PMID: 13408268.
